MC1550A1 - Forme de dosage orale - Google Patents

Forme de dosage orale

Info

Publication number
MC1550A1
MC1550A1 MC831659A MC1659A MC1550A1 MC 1550 A1 MC1550 A1 MC 1550A1 MC 831659 A MC831659 A MC 831659A MC 1659 A MC1659 A MC 1659A MC 1550 A1 MC1550 A1 MC 1550A1
Authority
MC
Monaco
Prior art keywords
dosage form
oral dosage
oral
dosage
Prior art date
Application number
MC831659A
Other languages
English (en)
Inventor
Charanjit Behl
George Beskid
Navnit Shah
Jacques Tossounian
Joel Unowsky
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MC1550A1 publication Critical patent/MC1550A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MC831659A 1982-10-15 1983-10-14 Forme de dosage orale MC1550A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/434,452 US4525339A (en) 1982-10-15 1982-10-15 Enteric coated oral dosage form

Publications (1)

Publication Number Publication Date
MC1550A1 true MC1550A1 (fr) 1984-08-31

Family

ID=23724297

Family Applications (1)

Application Number Title Priority Date Filing Date
MC831659A MC1550A1 (fr) 1982-10-15 1983-10-14 Forme de dosage orale

Country Status (14)

Country Link
US (1) US4525339A (fr)
EP (1) EP0108295A1 (fr)
JP (1) JPS59104312A (fr)
KR (1) KR840006437A (fr)
AU (1) AU2019283A (fr)
DK (1) DK473183A (fr)
FI (1) FI833728A (fr)
GR (1) GR82301B (fr)
IL (1) IL69960A0 (fr)
MC (1) MC1550A1 (fr)
NO (1) NO833757L (fr)
PT (1) PT77503A (fr)
ZA (1) ZA837307B (fr)
ZW (1) ZW22183A1 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60146825A (ja) * 1984-01-10 1985-08-02 Asahi Chem Ind Co Ltd 経口医薬製剤
CA1256799A (fr) * 1984-02-22 1989-07-04 Walter Fuller Suppositoires
US4760059A (en) * 1985-08-05 1988-07-26 Hoffmann-La Roche Inc. Rectal dosage form
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
ES2061623T3 (es) * 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
KR880012221A (ko) * 1987-04-13 1988-11-26 사노 가즈오 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
IE59934B1 (en) * 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
US5009894A (en) * 1988-03-07 1991-04-23 Baker Cummins Pharmaceuticals, Inc. Arrangement for and method of administering a pharmaceutical preparation
US5260271A (en) * 1988-06-22 1993-11-09 Applied Microbiology, Inc. Nisin compositions for use as enhanced broad range bactericides
US4925674A (en) * 1988-08-25 1990-05-15 Himedics, Inc. Amoxicillin microencapsulated granules
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
ZA898331B (en) * 1988-11-22 1990-07-25 Hoffmann La Roche Pharmaceutical compositions
ZA906186B (en) * 1989-09-11 1991-06-26 Hoffmann La Roche Pharmaceutical preparations
US6482516B1 (en) * 1993-07-20 2002-11-19 Banner Pharmacaps, Inc. Enrobed tablet
AT393955B (de) * 1990-03-30 1992-01-10 Martin Dr Leixnering Einrichtung zur nachbehandlung frischer beugesehnenverletzungen
US5342612A (en) * 1991-12-20 1994-08-30 American Cyanamid Company Compositions for the treatment of mammalian diseases
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5382435A (en) * 1993-03-24 1995-01-17 Southwest Research Institute Microparticulate pharmaceutical delivery system
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5559110A (en) * 1994-03-09 1996-09-24 The Dupont Merck Pharmaceutical Company Pharmaceutical formulations of cyclic urea type compounds
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
ATE414509T1 (de) * 1994-07-08 2008-12-15 Astrazeneca Ab Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
ATE386508T1 (de) * 1999-02-22 2008-03-15 Merrion Res I Ltd Feste orale dosierungsform enthaltend einen resorptionsverstärker
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US6248360B1 (en) 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
WO2001097851A2 (fr) 2000-06-21 2001-12-27 Cubist Pharmaceuticals, Inc. Compositions et methodes visant a ameliorer l'absorption orale d'agents anti-microbiens
WO2002004016A1 (fr) * 2000-07-11 2002-01-17 Shionogi & Co., Ltd. Preparations enteriques contenant des peptides physiologiquement actifs
WO2002092070A1 (fr) * 2001-05-11 2002-11-21 Elan Corporation, Plc Sels d'acide isostearique utilises comme accelerateurs de permeation
EP1390383B1 (fr) * 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Renforcateurs de permeation antisens
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
AU2003263024A1 (en) * 2002-04-23 2003-11-10 Christopher Mcconville Process of forming and modifying particles and compositions produced thereby
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p
US20050152969A1 (en) * 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
AU2006242535B2 (en) * 2005-04-29 2012-08-09 Merck Sharp & Dohme Corp. Therapeutic compositions
EP2526950A1 (fr) * 2006-04-07 2012-11-28 Merrion Research III Limited Forme pharmaceutique solide par voie orale contenant un activateur
US20070292512A1 (en) * 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CA2699172C (fr) * 2007-09-03 2016-05-17 Nanotherapeutics, Inc Compositions et methodes de distribution de medicaments peu solubles
JP2011500724A (ja) * 2007-10-19 2011-01-06 パーデュ リサーチ ファンデーション 結晶性化合物の固体製剤
KR20110007614A (ko) * 2008-05-07 2011-01-24 메리온 리서치 Ⅲ 리미티드 ＧｎＲＨ 관련 화합물의 조성물 및 제조 방법
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
JP2013514976A (ja) 2009-12-16 2013-05-02 ノッド ファーマシューティカルズ， インコーポレイテッド 経口薬物送達のための組成物および方法
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (fr) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Compositions pharmaceutiques d'inhibiteurs de facteur xa sélectifs destinées à une administration orale
CN103476419A (zh) 2011-01-07 2013-12-25 梅里翁第三研究有限公司 口服投药的含铁药物组合物
US20140228312A1 (en) * 2011-10-03 2014-08-14 Agency For Science, Technology And Research Antibiotic composition and its uses
EP3250191B1 (fr) 2015-01-29 2024-01-17 Novo Nordisk A/S Comprimés contenant un agoniste de glp-1 et revêtement gastro-résistant
WO2019036770A1 (fr) * 2017-08-24 2019-02-28 University Of South Australia Compositions antimicrobiennes et procédés d'utilisation

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE567598A (fr) *
US2476351A (en) * 1945-06-07 1949-07-19 Parke Davis & Co Injectable penicillin compositions
US2487336A (en) * 1946-02-25 1949-11-08 William E Hinds Penicillin product
US2443778A (en) * 1947-04-21 1948-06-22 Monroe J Romansky Preparations for penicillin therapy
US2566200A (en) * 1947-06-07 1951-08-28 Commercial Solvents Corp Oral therapeutic tablets
US2507193A (en) * 1949-05-17 1950-05-09 Bristol Lab Inc Penicillin product
US2805977A (en) * 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation
US2902407A (en) * 1955-06-14 1959-09-01 Commercial Solvents Corp Wax-coated penicillin product
US2864744A (en) * 1955-09-02 1958-12-16 American Home Prod Penicillin in solid dosage unit form
US3016330A (en) * 1955-11-10 1962-01-09 Novo Terapeutisk Labor As Therapeutical antibiotic composition
US2951014A (en) * 1957-01-03 1960-08-30 Upjohn Co Process for a stable oil suspension
US3402240A (en) * 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
NL297631A (fr) * 1963-06-03
US3849569A (en) * 1965-12-02 1974-11-19 Glaxo Lab Ltd Composition containing procaine penicillin
GB1226555A (fr) * 1967-08-08 1971-03-31
US3549746A (en) * 1967-11-02 1970-12-22 Bristol Myers Co Antibiotic composition
US3626056A (en) * 1967-11-02 1971-12-07 Bristol Myers Co Oral antibiotic product
US3538215A (en) * 1969-06-13 1970-11-03 Allied Chem Stabilized antibiotic in liquid ruminant feed supplement
GB1312918A (en) * 1969-07-08 1973-04-11 Beecham Group Ltd Veterinary treatment
US3696189A (en) * 1970-05-18 1972-10-03 Frank M Snyder Stabilized antibiotic and method
US3655864A (en) * 1970-09-21 1972-04-11 Smith Kline French Lab Glyceryl tristerate and higher fatty acid mixture for improving digestive absorption
JPS4971127A (fr) * 1972-11-18 1974-07-10
GB1413186A (en) * 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4145429A (en) * 1974-09-21 1979-03-20 Beecham Group Limited Oral veterinary preparations
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
GB1547164A (en) * 1975-08-14 1979-06-06 Beecham Group Ltd Veterinary compositions
JPS5231981A (en) * 1975-08-18 1977-03-10 Takeda Chem Ind Ltd Microcapsule preparation method
JPS5283924A (en) * 1976-01-01 1977-07-13 Sumitomo Chem Co Ltd Preparation of pharmaceuticals for rectal infusion containing penicill ins and cephalosporins
JPS6055486B2 (ja) * 1976-02-28 1985-12-05 富山化学工業株式会社 β−ラクタム環を有する化合物の直腸投与用組成物
JPS52139713A (en) * 1976-05-13 1977-11-21 Shionogi & Co Ltd Sustained release cefalexin preparations
DE2654844A1 (de) * 1976-12-03 1978-06-08 Kali Chemie Pharma Gmbh Verfahren zur herstellung fester loesungen von arzneistoffen zur oralen und rektalen applikation
US4250166A (en) * 1977-05-27 1981-02-10 Shionogi & Co., Ltd. Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
IL58462A0 (en) * 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a penicillin
GB2051574B (en) * 1979-05-10 1984-01-18 Kyoto Pharma Ind Adjuvant for promoting absorption of pharmacologically active substances through the rectum
JPS56104812A (en) * 1980-01-23 1981-08-20 Sankyo Co Ltd Production of cephalosporin compound preparation for rectal infusion
JPS5799519A (en) * 1980-12-12 1982-06-21 Toyo Jozo Co Ltd Stable suppository and its preparation

Also Published As

Publication number Publication date
FI833728A (fi) 1984-04-16
JPS59104312A (ja) 1984-06-16
NO833757L (no) 1984-04-16
PT77503A (en) 1983-11-01
EP0108295A1 (fr) 1984-05-16
GR82301B (fr) 1984-12-13
DK473183D0 (da) 1983-10-13
ZW22183A1 (en) 1985-04-17
ZA837307B (en) 1984-06-27
FI833728A0 (fi) 1983-10-13
AU2019283A (en) 1984-04-19
US4525339A (en) 1985-06-25
IL69960A0 (en) 1984-01-31
DK473183A (da) 1984-04-16
KR840006437A (ko) 1984-11-30

Similar Documents

Publication Publication Date Title
MC1550A1 (fr) Forme de dosage orale
IT1159561B (it) Manipolo dentistico
OA07621A (fr) Forme orale de clométacine et sa préparation.
FI833579A0 (fi) Eld-retarderande silikonaemnen foer plaster
IT8648450A0 (it) Composizione orale antitartaro
IT8648451A0 (it) Composizione orale antitartaro
IT1159558B (it) Manipolo dentistico
IT1159560B (it) Manipolo dentistico
IT1162879B (it) Composizioni farmaceutiche
IT1159559B (it) Manipolo dentistico
IT8747797A0 (it) Composizione orale antiplacca
DE3673761D1 (de) Feste orale antikariogenische zusammensetzung.
BR8307281A (pt) Derivados de pirazolina
DK88383D0 (da) Praeparat pa depotform
DK366083A (da) Uklar tandpasta
DE3371906D1 (de) Deazapurine derivatives
DE3688182D1 (de) Orale zusammensetzung.
AT376561B (de) Zahntechnischer artikulator
BR8304756A (pt) Conversao de gesso
FI831687A0 (fi) Farmaceutiska blandningar vilka innehaoller flere aktiva bestaondsdelar
ES525621A0 (es) Aparato de impresion
DK133283D0 (da) Doseringsapparat
DOP1983004180A (es) Derivados de acridanona
ES522651A0 (es) Procedimiento de preparacion de derivados de piperacina
SE8300828L (sv) Avtryckssked for dentala endamal

Legal Events

Date Code Title Description
YP Annual fee paid